Genfit seeks €150M to wrap up phase 3 NASH program

microscope image of nash
Nonalcoholic steatohepatitis (Michael Bonert/CC BY-SA 3.0)

Genfit is looking to raise €150 million ($177 million) to wrap up phase 3 development of its NASH candidate. The planned cash injection will also position Genfit to look to life beyond the phase 3 by supporting commercial preparations and the in-licensing of assets.

Lille, France-based Genfit is offering bonds owners can convert into shares or exchange for existing shares to raise the cash. The bond-based financing diverges from Genfit’s earlier fundraising moves and those being executed by other European biotechs, which are once again looking to Nasdaq for money. But Genfit CEO Jean-François Mouney thinks bonds have their advantages. 

“Genfit intends to carry out a different type of fund raise from the previous dilutive transactions and to take advantage of the leverage from 30% to 35% premium compared to the reference price included in the [bond] price,” Mouney said in a statement. “The fund raise offers a new type of institutional investor the opportunity to participate in Genfit`s development.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The French biotech has repeatedly expressed an interest in adding a Nasdaq listing to its existing spot on a European exchange in recent years. But, despite the IPO window reopening, it has opted against hitting go on that plan.

RELATED: Genfit moves liver disease pill into mid-stage, hints at upcoming IPO

From a near-term drug development perspective, the important thing is what the money enables Genfit to do, not where it comes from. In this regard, elafibranor, Genfit’s phase 3 NASH asset, is the centerpiece of the financing.

Genfit thinks the financing, when added to the €114 million it had at the last count, will see it through the elafibranor phase 3 and onto a filing for approval, provided the data are good enough. In parallel, Genfit will start gearing up to commercialize elafibranor in certain markets and advance the noninvasive diagnostic it thinks will identify which NASH patients need treating.  

The financing comes shortly after Intercept, one of Genfit’s closest rivals in the race for the NASH market, was hit by reports of deaths in its clinical trial. The FDA sent a warning to doctors about the risks posed by the candidate, particularly when it is given at too high a dose. Intercept’s stock is down 41% over the past month.

Both companies have raised as many questions as they have answered with the data generated to date. Those doubts about the data are spurring on a large chasing pack, which includes Allergan, Bristol-Myers Squibb and Gilead. 

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.